Biologics

A healthcare analytics company broke into the medtech market, acquiring Pur Biologics.

From approvals to acquisitions, here are eight developments in regenerative medicine to know since March 1.

The worldwide orthopedic regenerative surgical product market is expected to reach $5.6 billion by 2030, according to Research and Markets.

Kuros Biosciences' MagenetOs Flex Matrix was cleared by the FDA for use as a bone void filler in the posterolateral spine.

RTI Surgical, which develops biologic implants, is expanding its facility in Alachua, Fla., The Gainesville Sun reported April 18.

Bioventus has exercised its call option to acquire Israeli devicemaker CartiHeal for up to $450 million following the FDA's premarket approval of the Agili-C implant on March 29.

Orthopedic biologic company TheraCell was acquired by Isto Biologics, according to an April 5 news release.

Two-year data from a pilot study found the StemSpine regenerative procedure was effective for treating chronic lower back pain.

Zimmer Biomet has cemented a multiyear partnership with Biocomposites to exclusively distribute its Genex bone graft substitute in the U.S.

Becker's reported on five spine and orthopedic practices that have added regenerative medicine options in the last 90 days: